MaxCyte, Inc. - Result of Annual General Meeting

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE
MaxCyte Inc.
("MaxCyte" or the "Company")
Result of Annual General Meeting
The full text of the resolutions proposed and passed at the Annual General Meeting can be found in the proxy statement which was published and posted to stockholders on April 28, 2025 and copies of which are available in the SEC's EDGAR filing database on the SEC's website at www.sec.gov.
AIM Delisting
Among the resolutions passed by stockholders was a resolution for the cancellation of the admission of the Company's Common Stock to trading on AIM. Accordingly, it is expected that the last day of dealings in the Company's Common Stock on AIM will be
Following the delisting, there will be no public market in the
Further information regarding the delisting, including arrangements for how investors can continue to trade the Company's Common Stock on Nasdaq and other 'frequently asked questions', can be found at: https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a
For further information, please contact:
|
|
MaxCyte Contacts: US IR Adviser Gilmartin Group
|
+1 415-937-5400
|
|
|
|
Nominated Adviser and Joint Corporate Broker Panmure Liberum Corporate Broking |
+44 (0)20 7886 2500 |
|
|
|
ICR Healthcare |
+44 (0)203 709 5700
|
|
Additional Information
The person responsible for arranging the release of this information on behalf of the Company is
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.
It is important for you to know that:
(a) none of the Content is, or is intended to be, general or personal advice
(b) the principal purpose of the Content is to provide factual information only and to comment on news;
(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;
(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and
(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.
In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.
FOR OUR FULL DISCLAIMER CLICK HERE